Clinical Trial: Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758985) titled 'Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.' on Aug. 03.

Brief Summary: This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy, adult participants living in Mali.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Malaria

Intervention: DRUG: Cohort 1 low dose lotilaner with a high-fat meal

Participants will receive a single low dose of lotilaner with a high-fat meal

OTHER...